The clinical study of the safety and efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study
Latest Information Update: 26 May 2023
At a glance
- Drugs Istaroxime (Primary)
- Indications Acute heart failure; Decompensated heart failure
- Focus Proof of concept; Therapeutic Use
- Sponsors CVie Therapeutics; Lee's Pharmaceutical; Windtree Therapeutics
- 06 Apr 2020 According to a Windtree Therapeutics media release, the company presented a new subset analysis from a phase 2b study of istaroxime in patients hospitalized with acute heart failure (AHF) at the American College of Cardiology (ACC) 2020 virtual meeting.
- 06 Apr 2020 Results published in the Media Release
- 30 Mar 2020 Results of sub-analysis assessing istaroxime effect on E/e' and stroke volume index in Caucasian and Asian patients treated with istaroxime, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology